Opemalirsen

N/A

Report date: 2026/01/04 13:50:07
NME

Base Information

Drug NameOpemalirsen
Drug Alias NameAZD-2373IONIS-AZ5-2.5RxION-532
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionApolipoprotein L1 inhibitors
TargetsApolipoprotein L1
Therapy Area/IndicationsRenal Insufficiency, ChronicRenal Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca SaAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsRenal Insufficiency, ChronicRenal Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A